News

Carb-X News

Recommended

Carb-X
In the News

Antibiotic Resistance

Product Developer News

News Archive

  • 04.17.2024  |  As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene

    PHARMAVOICE | AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.

    Full Story

  • 03.08.2024  |  Professor Kevin Outterson speaks on antimicrobial resistance

    TUFTS DAILY | Kevin Outterson, a professor at Boston University, bridges economics, health equity and scientific research in his discussion about how to combat antimicrobial resistance.

    Full Story

  • 03.06.2024  |  Non-profits take over from Big Pharma in new drugs trials

    JUTA MEDICAL BRIEF | Effective, affordable antimicrobial drugs are desperately needed around the world, and last November, a clinical trial offered a glimmer of hope, when an oral antibiotic, called zoliflodacin, was shown to be effective against the bacterium that causes gonorrhoea.

    Full Story

  • 03.06.2024  |  CARB-X funds 100th project—a milestone for BU-based nonprofit leading antimicrobial-resistance fightback

    THE BRINK | Global partnership led by BU law professor has now given $452.6 million in funding to support promising new antibiotics, vaccines, and rapid diagnostics—and is ready to support more projects.

    Full Story

  • 03.05.2024  |  With new award, CARB-X hits the 100-project mark in battling antibiotic resistance

    CIDRAP | CARB-X today announced funding for its 100th project addressing antimicrobial resistance (AMR).

    Full Story

  • 02.28.2024  |  Can non-profits beat antibiotic resistance and soaring drug costs?

    NATURE | Last November, a clinical trial offered a glimmer of hope in the often gloomy fight against antimicrobial resistance. An oral antibiotic, called zoliflodacin, was shown to be effective against the bacterium that causes the sexually transmitted disease gonorrhoea.

    Full Story

  • 02.15.2024  |  Could a single synthetic molecule outsmart a variety of drug-resistant bacteria?

    LOS ANGELES TIMES | An estimated 2.8 million people in the U.S. contract infections each year from bacteria resistant to antibiotics, according to the U.S. Centers for Disease Control. More than 35,000 of them die.

    Full Story